What are the main functions and effects of Platinib?

Pralsetinib is an oral small molecule targeted drug that mainly targets malignant tumors caused by RET gene fusion or mutation. The RET gene plays an important role in the occurrence of various cancers. Platinib blocks the growth and spread of tumor cells by highly selectively inhibiting RET kinase activity. This mechanism allows Platinib to demonstrate significant clinical efficacy in the treatment of specific types of lung cancer, thyroid cancer and other diseases, especially for patients with RET gene alterations.

In the field of non-small cell lung cancer (NSCLC), platinib has been proven to significantly extend the progression-free survival of patients. For patients with RETfusion-positive non-small cell lung cancer, platinib can bring high objective response rates regardless of whether they have received previous treatment. At the same time, compared with traditional chemotherapy or immunotherapy, platinib's side effects are relatively controllable and well tolerated by patients. This makes it one of the important treatment options for patients with RETfusion-positive lung cancer.

Platinib also plays an important role in the treatment of thyroid cancer. For patients with RETmutated medullary thyroid cancer (MTC), platinib can not only effectively reduce tumor volume, but also delay disease progression. Even patients with advanced thyroid cancer who are refractory to radioactive iodine therapy can benefit from platinib treatment as long as RET-related changes are detected. This brings new hope to patients with refractory thyroid cancer.

Overall, the main efficacy and role of Platinib are reflected in precise targeting of RET changes, improved response rate, prolonged progression-free survival and lower side effects. With the deepening of more clinical studies, the application scope of platinib is expected to be further expanded, providing precise and effective treatment options for more patients with gene-driven cancers. In the future, with the continuous advancement of personalized treatment, platinib is expected to become one of the important drugs in the field of RET targeted therapy.

Reference materials:https://gavreto.com/